When a glioblastoma patient undergoes surgical resection followed by the standard Stupp protocol of temozolomide chemoradiation, follow-up magnetic resonance imaging scans frequently present an agonizing dilemma. In roughly 20% to 30% of cases, standard contrast-enhanced T1-weighted MRI reveals an expanding area of enhancement that looks identical to rapid tumor recurrence, but is actually pseudoprogression, a transient inflammatory breakdown of the blood-brain barrier induced by radiation.

Because standard gadolinium contrast agents leak indiscriminately across any disrupted vascular endothelium, clinicians have spent years relying on educated guesswork, serial surveillance scans, or invasive exploratory re-resections to make life-or-death decisions. The FDA approval of Telix Pharmaceuticals' Pixclara (floretyrosine F 18 or 18F-FET) formally converts molecular PET amino acid imaging from an academic investigational curiosity into a nationwide commercial standard of care.

In this deep dive, we are going to look at:

  • Why this matters now: Resolving the MRI pseudoprogression crisis
  • What actually happened: FDA NDA approval parameters and label scope
  • The obvious read versus the deeper signal: The theranostic supply chain moat
  • Category map: Diagnostic neuro-imaging vs targeted amino acid transport
  • The theranostic economic engine: Commercial radiopharmacy margins and HOPPS pass-through
  • The HealthTech Investor's Signal: Capital allocation, M&A catalysts, and cyclotron logistics
  • Counter-thesis and operational bottlenecks: Half-life physics and distribution density
  • Forward intelligence: 4 observable test milestones across 2026 to 2028
  • The Bottom Line for Health System Leaders and Life Science Investors